GMED Options Hit 52-Week Extreme Before Q3 Print

Globus Medical goes into tomorrow's Q3 results with options traders at their most defensive all year, even as short sellers pulled back meaningfully over the past week.

The clearest signal heading into the print is in the options market. The put/call ratio reached 0.88 on Monday, more than three standard deviations above its 20-day mean of 0.38, and the highest reading recorded in the past 52 weeks. That is a sharp reversal from the picture described in ORTEX's October 31 preview, where the PCR had collapsed to 0.29 on extreme call demand. In the two sessions since, options flow rotated hard toward puts. The stock closed at $79.58, down 1.6% on the week, underperforming a peer basket where the median weekly move was closer to flat. Borrow conditions remain uncrowded: availability is at 337%, meaning roughly three-and-a-half shares remain lendable for every one already borrowed, and the cost to borrow is just 0.56%, both consistent with a name where the lending market is not driving sentiment.

Short interest has eased since the October 31 preview but remains elevated in absolute terms. At 7.4% of free float, the short position has fallen roughly 9.5% over the past five sessions to around 8.25 million shares, continuing the covering trend noted last week. That retreat sits in contrast to the broader monthly trend, where short interest built by roughly 13% through October. With the ORTEX short score edging lower to 56.5 from above 58 a week ago, the momentum behind the short thesis is softening even as the absolute level stays meaningful. Wikipedia attention for the stock is running at a z-score of 3.1 against its own 90-day history, the highest retail attention reading in that window.

The analyst debate centres on whether Globus Medical's robotics-led strategy can sustain the revenue momentum shown in Q1, when organic growth came in at 11.2% and management raised full-year EPS guidance to $4.70-$4.80. Bulls point to a debt-free balance sheet, more than 30 new product launches since the NuVasive merger closed, and gross margins near 69%. Bears argue that slower adoption of ExcelsiusGPS robotics and competitive pressure from Medtronic, Stryker, and Zimmer Biomet could cap growth in the higher-value enabling technologies segment, with pricing pressure threatening the mid-70s gross margin target over time. The analyst consensus has shifted to hold, with multiple firms cutting targets through the second half of 2026 while keeping positive ratings. RBC's most recent move, lowering its target from $115 to $85 on October 1, is the sharpest single reduction in that period. The stock at $79.58 trades below every published target on the list, which ranges from $80 to $100.

Notably on the institutional side, Kayne Anderson Rudnick entered the register in Q3 with a new position of 4.28 million shares, the largest single-quarter addition among reported holders. BlackRock trimmed its stake, with its 13G/A filed October 27 showing a move from 9.1% to 8.0% of shares outstanding. All 13D/G stakes are as last disclosed around the 5% threshold and may not reflect current positions.

Tomorrow's print will test whether the Q3 revenue and margin trajectory justifies an analyst community that has spent the year trimming targets while holding constructive ratings, or confirms the more cautious read that the options market has suddenly pivoted to express.